Floatz logo

Autologous Bone Marrow Derived Cd34+ Hspcs Electroporated With Bcl11A Enhancer Targeting Cas9 Ribonucleoprotein

Transfusion Dependent Beta-Thalassaemia

Daniel Bauergene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Transfusion Dependent Beta-Thalassaemia cohort.

Asset / SponsorPhaseRating
Deferasirox
Pakistan Blood and Marrow Transplant (PBMT) Group
Phase 4BBB
Deferiprone
Pakistan Blood and Marrow Transplant (PBMT) Group
Phase 4BBB
Hydroxyurea
Bahria University
Phase 4BBB
DESFERRIOXAMINE B
Pakistan Blood and Marrow Transplant (PBMT) Group
Phase 4BBB
TACROLIMUS
M.D. Anderson Cancer Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Autologous Bone Marrow Derived Cd34+ Hspcs Electroporated With Bcl11A Enhancer Targeting Cas9 Ribonucleoprotein is also rated in:

beta thalassemiaDormant
CC
Indicative ·
41 / 100
View asset →
sickle cell diseaseDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →